Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

LDHA in neuroblastoma is associated with poor outcome and its depletion decreases neuroblastoma growth independent of aerobic glycolysis.

Dorneburg C, Fischer M, Barth TFE, Mueller-Klieser W, Hero B, Gecht J, Carter DR, De Preter K, Mayer B, Christner L, Speleman F, Marshall GM, Debatin KM, Beltinger C.

Clin Cancer Res. 2018 Jun 20. pii: clincanres.2578.2017. doi: 10.1158/1078-0432.CCR-17-2578. [Epub ahead of print]

PMID:
29925504
2.

Proof-of-principle that a decoy virus protects oncolytic measles virus against neutralizing antibodies.

Xu C, Goß AV, Dorneburg C, Debatin KM, Wei J, Beltinger C.

Oncolytic Virother. 2018 Apr 30;7:37-41. doi: 10.2147/OV.S150637. eCollection 2018.

3.

Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.

Chen A, Zhang Y, Meng G, Jiang D, Zhang H, Zheng M, Xia M, Jiang A, Wu J, Beltinger C, Wei J.

Sci Rep. 2017 Jul 12;7(1):5170. doi: 10.1038/s41598-017-05500-z.

4.

γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets.

Dorneburg C, Goß AV, Fischer M, Roels F, Barth TF, Berthold F, Kappler R, Oswald F, Siveke JT, Molenaar JJ, Debatin KM, Beltinger C.

Oncotarget. 2016 Sep 27;7(39):62799-62813. doi: 10.18632/oncotarget.11715.

5.

The mitochondrial genetic landscape in neuroblastoma from tumor initiation to relapse.

Riehl LM, Schulte JH, Mulaw MA, Dahlhaus M, Fischer M, Schramm A, Eggert A, Debatin KM, Beltinger C.

Oncotarget. 2016 Feb 9;7(6):6620-5. doi: 10.18632/oncotarget.6776.

6.

Boolean modeling identifies Greatwall/MASTL as an important regulator in the AURKA network of neuroblastoma.

Dahlhaus M, Burkovski A, Hertwig F, Mussel C, Volland R, Fischer M, Debatin KM, Kestler HA, Beltinger C.

Cancer Lett. 2016 Feb 1;371(1):79-89. doi: 10.1016/j.canlet.2015.11.025. Epub 2015 Nov 23.

PMID:
26616283
7.

Mitophagy switches cell death from apoptosis to necrosis in NSCLC cells treated with oncolytic measles virus.

Xia M, Meng G, Jiang A, Chen A, Dahlhaus M, Gonzalez P, Beltinger C, Wei J.

Oncotarget. 2014 Jun 15;5(11):3907-18.

8.

Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.

Lühl NC, Zirngibl F, Dorneburg C, Wei J, Dahlhaus M, Barth TF, Meyer LH, Queudeville M, Eckhoff S, Debatin KM, Beltinger C.

Haematologica. 2014 Jun;99(6):1050-61. doi: 10.3324/haematol.2013.087205. Epub 2014 Apr 3.

9.

Mitophagy enhances oncolytic measles virus replication by mitigating DDX58/RIG-I-like receptor signaling.

Xia M, Gonzalez P, Li C, Meng G, Jiang A, Wang H, Gao Q, Debatin KM, Beltinger C, Wei J.

J Virol. 2014 May;88(9):5152-64. doi: 10.1128/JVI.03851-13. Epub 2014 Feb 26.

10.

MYCN and survivin cooperatively contribute to malignant transformation of fibroblasts.

Hipp NI, Christner L, Wirth T, Mueller-Klieser W, Walenta S, Schröck E, Debatin KM, Beltinger C.

Carcinogenesis. 2014 Feb;35(2):479-88. doi: 10.1093/carcin/bgt341. Epub 2013 Oct 15.

PMID:
24130166
11.

Generation of murine sympathoadrenergic progenitor-like cells from embryonic stem cells and postnatal adrenal glands.

Saxena S, Wahl J, Huber-Lang MS, Stadel D, Braubach P, Debatin KM, Beltinger C.

PLoS One. 2013 May 10;8(5):e64454. doi: 10.1371/journal.pone.0064454. Print 2013.

12.

CD57(high) neuroblastoma cells have aggressive attributes ex situ and an undifferentiated phenotype in patients.

Schlitter AM, Dorneburg C, Barth TF, Wahl J, Schulte JH, Brüderlein S, Debatin KM, Beltinger C.

PLoS One. 2012;7(8):e42025. doi: 10.1371/journal.pone.0042025. Epub 2012 Aug 10.

13.

Mitochondrial genome variants in non-remitting ALL of childhood.

Back C, Knauss H, Ludwig WD, Schrappe M, Debatin KM, Beltinger C.

Br J Haematol. 2011 Dec;155(5):626-9. doi: 10.1111/j.1365-2141.2011.08743.x. Epub 2011 May 25. No abstract available.

PMID:
21615382
14.

Ewing's sarcoma cells with CD57-associated increase of tumorigenicity and with neural crest-like differentiation capacity.

Wahl J, Bogatyreva L, Boukamp P, Rojewski M, van Valen F, Fiedler J, Hipp N, Debatin KM, Beltinger C.

Int J Cancer. 2010 Sep 1;127(6):1295-307. doi: 10.1002/ijc.25163.

15.

Endothelial progenitor cells for cancer gene therapy.

Debatin KM, Wei J, Beltinger C.

Gene Ther. 2008 May;15(10):780-6. doi: 10.1038/gt.2008.36. Epub 2008 Mar 27. Review.

PMID:
18369327
16.

N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells.

Ushmorov A, Hogarty MD, Liu X, Knauss H, Debatin KM, Beltinger C.

Oncogene. 2008 May 29;27(24):3424-34. doi: 10.1038/sj.onc.1211017. Epub 2008 Jan 14.

PMID:
18193081
17.

Targeted release of oncolytic measles virus by blood outgrowth endothelial cells in situ inhibits orthotopic gliomas.

Wei J, Wahl J, Nakamura T, Stiller D, Mertens T, Debatin KM, Beltinger C.

Gene Ther. 2007 Nov;14(22):1573-86. Epub 2007 Sep 27.

PMID:
17898797
18.

[Tumour stem cells--a new concept in tumour biology].

Hatina J, Schulz WA, Fischer J, Wahl J, Debatin KM, Beltinger C.

Dtsch Med Wochenschr. 2007 Aug;132(31-32):1629-32. Review. German.

PMID:
17654417
19.

Infiltration of blood outgrowth endothelial cells into tumor spheroids: role of matrix metalloproteinases and irradiation.

Wei J, Zhou S, Bachem MG, Debatin KM, Beltinger C.

Anticancer Res. 2007 May-Jun;27(3B):1415-21.

20.

Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells.

Wei J, Wahl J, Knauss H, Zeller S, Jarmy G, Fitze G, Debatin KM, Beltinger C.

Cancer Gene Ther. 2007 Jul;14(7):640-51. Epub 2007 Apr 20.

PMID:
17479107
21.

Enriching suicide gene bearing tumor cells for an increased bystander effect.

Unger MM, Wahl J, Ushmorov A, Buechele B, Simmet T, Debatin KM, Beltinger C.

Cancer Gene Ther. 2007 Jan;14(1):30-8. Epub 2006 Oct 6.

PMID:
17024230
22.

Human blood late outgrowth endothelial cells for gene therapy of cancer: determinants of efficacy.

Wei J, Jarmy G, Genuneit J, Debatin KM, Beltinger C.

Gene Ther. 2007 Feb;14(4):344-56. Epub 2006 Oct 5.

PMID:
17024106
23.

Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.

Baader E, Toloczko A, Fuchs U, Schmid I, Beltinger C, Ehrhardt H, Debatin KM, Jeremias I.

Cancer Res. 2005 Sep 1;65(17):7888-95.

24.

Caspase-8L expression protects CD34+ hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis.

Mohr A, Zwacka RM, Jarmy G, Büneker C, Schrezenmeier H, Döhner K, Beltinger C, Wiesneth M, Debatin KM, Stahnke K.

Oncogene. 2005 Mar 31;24(14):2421-9.

PMID:
15735742
25.

Growth inhibition of murine neuroblastoma cells by c-myc with cell cycle arrest in G2/M.

Ushmorov A, Debatin KM, Beltinger C.

Cancer Biol Ther. 2005 Feb;4(2):181-6. Epub 2005 Feb 8.

PMID:
15684616
26.

Embryonic endothelial progenitor cells armed with a suicide gene target hypoxic lung metastases after intravenous delivery.

Wei J, Blum S, Unger M, Jarmy G, Lamparter M, Geishauser A, Vlastos GA, Chan G, Fischer KD, Rattat D, Debatin KM, Hatzopoulos AK, Beltinger C.

Cancer Cell. 2004 May;5(5):477-88.

27.

Combination suicide gene therapy.

Uckert W, Salmons B, Beltinger C, Günzburg WH, Kammertöns T.

Methods Mol Med. 2004;90:345-52. No abstract available.

PMID:
14657572
28.

Endothelial progenitor cell culture and differentiation in vitro: a methodological comparison using human umbilical cord blood.

Eggermann J, Kliche S, Jarmy G, Hoffmann K, Mayr-Beyrle U, Debatin KM, Waltenberger J, Beltinger C.

Cardiovasc Res. 2003 May 1;58(2):478-86.

PMID:
12757882
29.

TRAIL enhances thymidine kinase/ganciclovir gene therapy of neuroblastoma cells.

Beltinger C, Fulda S, Walczak H, Debatin KM.

Cancer Gene Ther. 2002 Apr;9(4):372-81.

30.

Murine models for experimental therapy of pediatric solid tumors with poor prognosis.

Beltinger C, Debatin KM.

Int J Cancer. 2001 May 1;92(3):313-8. Review.

31.

Suicide gene therapy for pediatric tumors.

Beltinger C, Uckert W, Debatin KM.

J Mol Med (Berl). 2001;78(11):598-612. Review.

PMID:
11269507
32.

Mitochondrial amplification of death signals determines thymidine kinase/ganciclovir-triggered activation of apoptosis.

Beltinger C, Fulda S, Kammertoens T, Uckert W, Debatin KM.

Cancer Res. 2000 Jun 15;60(12):3212-7.

33.

Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases.

Beltinger C, Fulda S, Kammertoens T, Meyer E, Uckert W, Debatin KM.

Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8699-704.

35.

[The role of CD95 (APO-1/Fas) mutations in lymphoproliferative and malignant lymphatic diseases].

Beltinger C, Böhler T, Schrappe M, Ludwig WD, Debatin KM.

Klin Padiatr. 1998 Jul-Aug;210(4):153-8. Review. German.

PMID:
9743945
36.

Mutation analysis of CD95 (APO-1/Fas) in childhood B-lineage acute lymphoblastic leukaemia.

Beltinger C, Böhler T, Karawajew L, Ludwig WD, Schrappe M, Debatin KM.

Br J Haematol. 1998 Aug;102(3):722-8.

PMID:
9722299
37.

CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia.

Beltinger C, Kurz E, Böhler T, Schrappe M, Ludwig WD, Debatin KM.

Blood. 1998 May 15;91(10):3943-51.

38.

Human Krüppel-related 3 (HKR3): a candidate for the 1p36 neuroblastoma tumour suppressor gene?

Maris JM, Jensen J, Sulman EP, Beltinger CP, Allen C, Biegel JA, Brodeur GM, White PS.

Eur J Cancer. 1997 Oct;33(12):1991-6.

PMID:
9516840
39.

Molecular analysis of the region of distal 1p commonly deleted in neuroblastoma.

White PS, Maris JM, Sulman EP, Jensen SJ, Kyemba SM, Beltinger CP, Allen C, Kramer DL, Biegel JA, Brodeur GM.

Eur J Cancer. 1997 Oct;33(12):1957-61.

PMID:
9516832
40.

Whole genome amplification of single cells from clinical peripheral blood smears.

Beltinger CP, Klimek F, Debatin KM.

Mol Pathol. 1997 Oct;50(5):272-5.

41.

Regulation of apoptosis through CD95 (APO-I/Fas) receptor-ligand interaction.

Debatin KM, Beltinger C, Böhler T, Fellenberg J, Friesen C, Fulda S, Herr I, Los M, Scheuerpflug C, Sieverts H, Stahnke K.

Biochem Soc Trans. 1997 May;25(2):405-10. Review. No abstract available.

PMID:
9191126
42.

Cloning, chromosomal localization, physical mapping, and genomic characterization of HKR3.

Maris JM, Jensen SJ, Sulman EP, Beltinger CP, Gates K, Allen C, Biegel JA, Brodeur GM, White PS.

Genomics. 1996 Jul 15;35(2):289-98.

PMID:
8661141
43.

Physical mapping and genomic structure of the human TNFR2 gene.

Beltinger CP, White PS, Maris JM, Sulman EP, Jensen SJ, LePaslier D, Stallard BJ, Goeddel DV, de Sauvage FJ, Brodeur GM.

Genomics. 1996 Jul 1;35(1):94-100.

PMID:
8661109
44.

Significance of chromosome 1p loss of heterozygosity in neuroblastoma.

Maris JM, White PS, Beltinger CP, Sulman EP, Castleberry RP, Shuster JJ, Look AT, Brodeur GM.

Cancer Res. 1995 Oct 15;55(20):4664-9.

45.

A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3.

White PS, Maris JM, Beltinger C, Sulman E, Marshall HN, Fujimori M, Kaufman BA, Biegel JA, Allen C, Hilliard C, Valentine MB, Look AT, Enomoto H, Sakiyama S, Brodeur GM.

Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5520-4.

46.

No CDKN2 mutations in neuroblastomas.

Beltinger CP, White PS, Sulman EP, Maris JM, Brodeur GM.

Cancer Res. 1995 May 15;55(10):2053-5.

47.

Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides.

Beltinger C, Saragovi HU, Smith RM, LeSauteur L, Shah N, DeDionisio L, Christensen L, Raible A, Jarett L, Gewirtz AM.

J Clin Invest. 1995 Apr;95(4):1814-23.

48.
49.

Sonography of subependymal cysts in congenital rubella syndrome.

Beltinger C, Saule H.

Eur J Pediatr. 1988 Dec;148(3):206-7.

PMID:
3063530
50.

Imaging of lipoma of the corpus callosum and intracranial dermoids in the Goldenhar syndrome.

Beltinger C, Saule H.

Pediatr Radiol. 1988;18(1):72-3. No abstract available.

PMID:
3277142

Supplemental Content

Loading ...
Support Center